Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
-
Patent number: 11944600Abstract: The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective effects in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with amyotrophic lateral sclerosis (ALS). Furthermore, the combination of the cannabinoid tetrahydrocannabinol (THC) with the drug olexisome provided a synergistic disease modifying effect in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with ALS.Type: GrantFiled: July 10, 2018Date of Patent: April 2, 2024Assignee: GW Research LimitedInventors: Benjamin Whalley, William Hind, Royston Gray, Javier Fernandez-Ruiz, Eva De Lago, Carmen Rodriguez-Cueto, Laura Garcia-Toscano, Irene Santos-Garcia
-
Patent number: 11866415Abstract: Provided herein is a method of forming a beta-lactone from a carboxylic acid having a beta-carbon with a hydrogen atom disposed thereon. The method comprises contacting a carboxylic acid of formula (1) as described herein with an effective amount of a palladium(II) catalyst, an effective amount of an N-protected aminoacid ligand, and t-butylhydroperoxide in a solvent comprising hexafluoroisopropanol (HFIP), at about 60° C. to provide a beta-lactone of formula (2) as described herein.Type: GrantFiled: May 29, 2020Date of Patent: January 9, 2024Assignee: The Scripps Research InstituteInventors: Jin-quan Yu, Zhe Zhuang
-
Patent number: 11850230Abstract: The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF, and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit a TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.Type: GrantFiled: October 6, 2022Date of Patent: December 26, 2023Assignee: ILAbInventors: Tae-Hwe Heo, Kye Jung Shin
-
Patent number: 11806352Abstract: Theobromine for use in the treatment of increasing HDL-cholesterol and/or increasing the ratio HDL-cholesterol:LDL-cholesterol in humans and the use of theobromine for increasing HDL-cholesterol in humans, and/or for increasing the ratio HDL-C/LDL-C, and compositions comprising theobromine.Type: GrantFiled: May 16, 2011Date of Patent: November 7, 2023Assignee: UPFIELD EUROPE B.V.Inventors: Richard Draijer, Bert-Jan Hendrik Van Den Born
-
Patent number: 11786555Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.Type: GrantFiled: December 16, 2020Date of Patent: October 17, 2023Assignee: Io Therapeutics, Inc.Inventors: Roshantha A. Chandraratna, Martin E. Sanders
-
Patent number: 11779562Abstract: The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.Type: GrantFiled: July 14, 2022Date of Patent: October 10, 2023Assignee: Zelira Therapeutics Operations Pty LtdInventors: Harry Karelis, Mara Gordon, Stewart Smith, Stewart Washer
-
Patent number: 11771679Abstract: The present invention discloses a composition containing hesperetin and synergistic hypoglycemic application thereof, and belongs to the technical field of natural active compounds. The composition of the present invention contains the hesperetin and a compound X, and the compound X is galangin or formononetin, where a mass ratio of the hesperetin to the galangin is 30:100, and a mass ratio of the hesperetin to the formononetin is 30:20. The composition of the present invention has an obvious synergistic effect of inhibiting ?-glucosidase, and the effect thereof is better than that of using the flavonoid compound alone, and may reduce a dosage of the use of drugs and occurrence of drug resistance.Type: GrantFiled: December 15, 2022Date of Patent: October 3, 2023Assignee: ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCESInventors: Qiang Zhang, Zhonggao Jiao, Dalei Chen, Jiechao Liu, Wenbo Yang, Chunling Zhang, Hui Liu, Zhenzhen Lv, Junkun Pan
-
Patent number: 11753416Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.Type: GrantFiled: July 6, 2021Date of Patent: September 12, 2023Assignee: Novartis AGInventors: Ha-Soon Choi, Jiqing Jiang, James Paul Lajiness, Bao Nguyen, Hank Michael James Petrassi
-
Patent number: 11737996Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.Type: GrantFiled: December 16, 2020Date of Patent: August 29, 2023Assignee: Io Therapeutics, Inc.Inventors: Roshantha A. Chandraratna, Martin E. Sanders
-
Patent number: 11707557Abstract: Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.Type: GrantFiled: February 3, 2022Date of Patent: July 25, 2023Assignee: Cook Medical Technologies LLCInventor: John K. Jackson
-
Patent number: 11654118Abstract: A composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid is provided. The disclosure further provides a method of treating inflammation comprising administering a composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid to a patient in need thereof. The disclosure further provides a method of treating inflammation including administering a composition including protocatechuic acid and a composition including a cannabinoid to a patient in need thereof. In embodiments, the composition including protocatechuic acid and the composition including a cannabinoid may be administered simultaneously within about 60 minutes of each other. In embodiments, the cannabinoid includes Cannabidiol (CBD).Type: GrantFiled: September 13, 2022Date of Patent: May 23, 2023Inventor: Lanny Leo Johnson
-
Patent number: 11648222Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.Type: GrantFiled: December 29, 2020Date of Patent: May 16, 2023Assignees: IO Therapeutics, Inc., The Johns Hopkins UnivercityInventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
-
Patent number: 11622988Abstract: The present disclosure provides an extract of early-harvested Citrus reticulata fruit, and a method for reducing lipid accumulation by using the extract of early-harvested Citrus reticulata fruit. The extract of early-harvested Citrus reticulata fruit includes tetramethylisoscutellarein.Type: GrantFiled: May 19, 2021Date of Patent: April 11, 2023Assignee: TCI CO., LTD.Inventor: Yung-Hsiang Lin
-
Patent number: 11617725Abstract: A composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid is provided. The disclosure further provides a method of treating inflammation comprising administering a composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid to a patient in need thereof. The disclosure further provides a method of treating inflammation including administering a composition including protocatechuic acid and a composition including a cannabinoid to a patient in need thereof. In embodiments, the composition including protocatechuic acid and the composition including a cannabinoid may be administered simultaneously within about 60 minutes of each other. In embodiments, the cannabinoid includes Cannabidiol (CBD).Type: GrantFiled: April 20, 2022Date of Patent: April 4, 2023Inventor: Lanny Leo Johnson
-
Patent number: 11612616Abstract: Compositions comprising aldehyde functional monoterpenoids in combination with 3,3?,4?,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19.Type: GrantFiled: May 3, 2021Date of Patent: March 28, 2023Inventor: William B. Coe
-
Patent number: 11583514Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.Type: GrantFiled: September 17, 2020Date of Patent: February 21, 2023Assignee: MEI Pharma, Inc.Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
-
Patent number: 11554153Abstract: Compositions and methods for bone health, cartilage health or both, are disclosed that include preparing and utilizing a mixture of at least one Morus extract enriched for one or more prenylated flavonoids, at least one Scutellaria extract enriched for one or more free-B-ring flavonoids, and at least one Acacia extract enriched for one or more flavans.Type: GrantFiled: March 9, 2020Date of Patent: January 17, 2023Assignee: Unigen, Inc.Inventors: Qi Jia, Ping Jiao, Mesfin Yimam, Teresa Horm
-
Patent number: 11547715Abstract: A drug that contains chlorogenic acid is effective in treating chordoma. When administered to a patient in need thereof, chlorogenic acid can significantly inhibit the proliferation of chordoma cells, reduce the expression level of multi-drug resistance gene MDR1 of chordoma cells, reverse the multi-drug resistance of chordoma cells, and effectively treat chordoma disease.Type: GrantFiled: December 27, 2018Date of Patent: January 10, 2023Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Yazhuo Zhang, Mengtian Zhang
-
Patent number: 11547691Abstract: Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.Type: GrantFiled: December 16, 2019Date of Patent: January 10, 2023Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UAB RESEARCH FOUNDATIONInventors: Bill J. Baker, Lindsey N. Shaw, Andrew Jason Shilling, Alexandre Jean Bory, Jessie Allen (Adams), Charles Dunkle Amsler, Jr., James Bruce McClintock
-
Patent number: 11504349Abstract: The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF, and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit a TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.Type: GrantFiled: July 12, 2018Date of Patent: November 22, 2022Assignee: ILABInventors: Tae-Hwe Heo, Kye Jung Shin
-
Patent number: 11497719Abstract: Disclosed are a cannabinoid composition and an application of the same in preparing a medicine for treating neurodegenerative diseases, so as to solve the drawbacks of conventional medicines such as serious side effects and degraded therapeutic effect after long-term administration. The cannabinoid composition includes: cannabidiol and cannabigerol, a mass ratio of the cannabidiol to the cannabigerol ranging from 1:1 to 1:10, or from 1:0.3 to 1:0.5, or from 1:0.5 to 1:0.7, or from 1:07 to 1:1.Type: GrantFiled: January 27, 2022Date of Patent: November 15, 2022Inventors: Chendong Zou, Hei Tai, Guijiang Wang, Wan Xiao, Sui Huang
-
Patent number: 11491136Abstract: Neuropeptide FF receptor modulators based on a proline scaffold are provided which offer NPFF receptor potencies in the nanomolar range and antagonistic selectivity for the NPFF1 receptor. Methods, compounds and compositions for modulating the function of neuropeptide FF receptors are provided for pharmacotherapies capable of influencing conditions or disorders affected by the neuropeptide FF receptors.Type: GrantFiled: February 13, 2018Date of Patent: November 8, 2022Assignee: RESEARCH TRIANGLE INSTITUTEInventors: Yanan Zhang, Thuy Nguyen
-
Patent number: 11491134Abstract: A composition for inhibiting skin cell proliferation and/or anti-inflammation is provided. The composition for inhibiting skin cell proliferation and/or anti-inflammation includes: apigenin and luteolin, wherein a weight ratio of the apigenin to the luteolin is about 1.5-25:1, or a mole ratio of the apigenin to the luteolin is about 1.5-25:1. Moreover, the apigenin and the luteolin have a synergistic effect on inhibiting skin cell proliferation and/or anti-inflammation.Type: GrantFiled: December 31, 2019Date of Patent: November 8, 2022Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: I-Hong Pan, Ming-Han Li, Kai-An Chuang, Shu-Fang Wen
-
Patent number: 11458117Abstract: Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of ? secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of ? secretase mediated disorders.Type: GrantFiled: June 14, 2018Date of Patent: October 4, 2022Assignee: SAMI LABS LIMITEDInventors: Muhammed Majeed, Kalyanam Nagabhushanam
-
Patent number: 11395814Abstract: The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain/penetration disorders; vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest/arousal disorder, low female libido, and female orgasmic disorder.Type: GrantFiled: April 14, 2020Date of Patent: July 26, 2022Inventor: Wendy Anne Epstein
-
Patent number: 11364220Abstract: Compounds described herein are inhibitors of retinoic add inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.Type: GrantFiled: November 26, 2020Date of Patent: June 21, 2022Assignee: Queen's University at KingstonInventors: Donald Andrew Cameron, Martin Petkovich, Toni Kristian Rantanen, Victor Snieckus, Johnathan Board, Suneel Singh, Ashishkumar Jayantilal Maheta
-
Patent number: 11337935Abstract: Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggregate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.Type: GrantFiled: March 25, 2019Date of Patent: May 24, 2022Inventors: Isabella A. Graef, Mamoun M. Alhamadsheh
-
Patent number: 11337934Abstract: A composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid is provided. The disclosure further provides a method of treating inflammation comprising administering a composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid to a patient in need thereof. The disclosure further provides a method of treating inflammation including administering a composition including protocatechuic acid and a composition including a cannabinoid to a patient in need thereof. In embodiments, the composition including protocatechuic acid and the composition including a cannabinoid may be administered simultaneously within about 60 minutes of each other. In embodiments, the cannabinoid includes Cannabidiol (CBD).Type: GrantFiled: April 8, 2021Date of Patent: May 24, 2022Inventor: Lanny Leo Johnson
-
Patent number: 11330829Abstract: An oil or fat for tempering type chocolate capable of enhancing and maintaining original flavors (milk taste, sweet taste, and cacao flavor, etc.) of chocolate is described, being obtained by blending therein 0.3 to 15% of a randomly transesterified oil of which a raw material is an oil or fat having a content of saturated fatty acids of 5 to 50% in the constituent fatty acids thereof and by further containing 5 to 50 ppm of malonyl isoflavone glycoside. A chocolate in which the oil or fat is blended is also described.Type: GrantFiled: October 1, 2014Date of Patent: May 17, 2022Assignee: FUJI OIL HOLDINGS INC.Inventors: Masako Okochi, Masayuki Matsui, Chie Nagashima, Chika Aramaki
-
Patent number: 11312695Abstract: Methods and compositions are provided for increasing muscle hypertrophy, e.g., through the administration of novel combinations of natural products that inhibit SIRT1.Type: GrantFiled: February 23, 2021Date of Patent: April 26, 2022Assignees: The Regents of the University of California, University of BirminghamInventors: Keith Baar, Andrew Philp, Simon Schenk
-
Patent number: 11298334Abstract: Disclosed is the use of isothiocyanate compounds. In particular, disclosed is the use of a compound as shown by Formula (I) or a derivative as shown by Formula (II) in the manufacture of a composition or preparation for preventing and/or treating hyperlipidemia. The compound of the present invention can reduce the levels of triglycerides and low density lipoproteins in the serum of mammals (such as rats and humans), increase the level of high density lipoproteins in the serum, and reduce the level of total bilirubin in the serum of mammals (such as rats and humans).Type: GrantFiled: April 20, 2017Date of Patent: April 12, 2022Assignee: JC (WUXI) COMPANY, INC.Inventors: Jingcai Cheng, Chunxia Zhang, Zhiwei Cheng
-
Patent number: 11298307Abstract: The present invention relates to a transparent or semitransparent cosmetic composition in which the stability of amentoflavone is enhanced, and more particularly, to a transparent or semitransparent cosmetic composition, wherein a water-soluble amentoflavone-oligomer complex, in which amentoflavone is encapsulated in a hollow structure of an oligomer structure, is stabilized in a second agent containing a polyhydric alcohol, a two-liquid-type container is used to mix first and second agents before use, and hydrotrope is contained in the first agent to increase the mixing stability of the first and second agents and thereby enhance the stability of amentoflavone.Type: GrantFiled: March 26, 2018Date of Patent: April 12, 2022Assignee: Amorepacific CorporationInventors: Byung Ryol Paik, Soon Ae An, Joon Young Hwang, Yong Jin Kim, Byung Fhy Suh
-
Patent number: 11273144Abstract: The present invention relates to compounds and compositions and their applications as pharmaceuticals for treating, preventing, or reversing injury to skeletal or cardiac muscles, for treating or preventing diseases relating to the structure and function of skeletal or cardiac muscle, and for inducing regeneration or restructuring of skeletal or cardiac muscle as a means of treating diseases relating to abnormalities in skeletal or cardiac muscle structure and function in a human or animal subject. Further aspects relate to the same or similar applications for bone and bone diseases.Type: GrantFiled: January 14, 2020Date of Patent: March 15, 2022Assignee: EPIRIUM BIO INC.Inventors: George Frederic Schreiner, Guillermo Ceballos, Sundeep Dugar
-
Patent number: 11241406Abstract: Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate/nitrite levels, and inhibiting myeloperoxidase activity.Type: GrantFiled: August 28, 2016Date of Patent: February 8, 2022Assignee: Nature's Sunshine Products, Inc.Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Mohan Kaadige, Wei Gao
-
Patent number: 11207313Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising a non-bile farnesoid X receptor (FXR) agonist 2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one lipid excipient; to a capsule for oral administration comprising said pharmaceutical composition; to the use of said pharmaceutical composition for the treatment of a FXR mediated disorder or condition; and to a process for preparing said pharmaceutical composition.Type: GrantFiled: September 10, 2018Date of Patent: December 28, 2021Assignee: Novartis AGInventors: Claus Dieter Bischoff, Sonali Bose, Geoffrey Gogniat
-
Patent number: 11185527Abstract: There is a continuing need for methods and compositions relating to hormone-receptor-dependent cancers, including pharmaceutical compositions including one or more compounds having activity against steroid hormone-receptor-dependent cancer and methods of treatment of a steroid hormone-receptor-dependent cancer in a subject using said pharmaceutical compositions. ELK1 is a steroid hormone receptor tethering, protein that is implicated in hormone receptor dependent cancers. Compositions and methods according to aspects of the present invention inhibit the association of steroid hormone receptors with ELK1 providing activity against steroid hormone-receptor-dependent cancer.Type: GrantFiled: June 26, 2018Date of Patent: November 30, 2021Assignee: Wayne State UniversityInventor: Manohar Ratnam
-
Patent number: 11147791Abstract: An object of the present invention is to provide a novel composition for use in activating a sympathetic nerve. The present invention provides a composition for use in activating a sympathetic nerve, comprising a polyphenol as an active ingredient. The polyphenol comprises 25% by mass or more of monomeric to tetrameric polyphenols, and the monomeric to tetrameric polyphenols include at least catechin, epicatechin, procyanidin B2, procyanidin B5, procyanidin C1 and cinnamtannin A2.Type: GrantFiled: November 28, 2017Date of Patent: October 19, 2021Inventors: Kazuji Tamura, Hiroki Ohara
-
Patent number: 11135261Abstract: Provided are liquid and powder grape extracts having elevated phenolic content. The extracts can be made from grape seeds, grape skins, or a combination thereof. In some instances, extracts may be blends of grape seed extracts and grape skin extracts. Methods of manufacturing such extracts area also provided. Such methods involve controlled temperature conditions to increase yield of phenolic compounds in the extracts. Methods of using the extraction for treating subjects are also provided, including treatment of cancer and end-organ damage relating to hypertension.Type: GrantFiled: April 3, 2017Date of Patent: October 5, 2021Assignee: PIEDMONT RESEARCH & DEVELOPMENT CORPORATIONInventor: Jerry Wayne Smith
-
Patent number: 11110105Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.Type: GrantFiled: April 11, 2018Date of Patent: September 7, 2021Assignee: INSTITUT GUSTAVE ROUSSYInventors: Sébastien Apcher, Alison Pierson, Mathilde Boulpicante, Zafiarisoa Dolor Renko, Mouad Alami, Romain Darrigrand
-
Patent number: 11098053Abstract: Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.Type: GrantFiled: April 4, 2014Date of Patent: August 24, 2021Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Amy Strong, Stephen Boue, Matthew Burow, Bruce Bunnell, Quan Jiang, Shilong Zheng, Guangdi Wang
-
Patent number: 11091499Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.Type: GrantFiled: June 7, 2018Date of Patent: August 17, 2021Assignee: Novartis AGInventors: Ha-Soon Choi, Jiqing Jiang, James Paul Lajiness, Bao Nguyen, Hank Michael James Petrassi
-
Patent number: 11090286Abstract: The present invention provides methods and compositions for treating or preventing breast cancer with S-equol. The method and compositions are particularly suited to treating triple-negative breast cancer. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.Type: GrantFiled: April 15, 2019Date of Patent: August 17, 2021Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Rong Li, Bin Yuan, Tyler Curiel
-
Patent number: 11083197Abstract: An herbicidal composition comprising one or more compounds of Formula I: where R1 and R2 are H or taken together with the carbon atoms to which the are attached form a furane ring; R3 and R4 each independently represent H, —OH or —O—(C1-C4) alkyl; and R5 is H, (C1-C4) alkyl, —(C1-C2) alkylene-O-glucoside or —COOH; and an agriculturally acceptable vehicle. There is also disclosed a method for weed control by application of compounds of Formula I and the use of the composition for controlling weeds.Type: GrantFiled: December 30, 2016Date of Patent: August 10, 2021Assignees: Investigaciones Biologicas en Agroquimicos Rosario S.A., The United States of America, as represented by the Secretary of AgricultureInventors: Gustavo M. Sosa, Lucia M. Travaini, Helmut Walter, Charles Cantrell, Stephen Duke, Nestor Carrillo, Eduardo Ceccarelli
-
Patent number: 11058665Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.Type: GrantFiled: September 13, 2019Date of Patent: July 13, 2021Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Joan Massague, Adrienne Boire, Qing Chen
-
Patent number: 11052124Abstract: The present disclosure provides an extract of early-harvested Citrus reticulata fruit, and a method for reducing lipid accumulation by using the extract of early-harvested Citrus reticulata fruit. The extract of early-harvested Citrus reticulata fruit includes tetramethylisoscutellarein.Type: GrantFiled: August 7, 2019Date of Patent: July 6, 2021Assignee: TC1 CO., LTD.Inventor: Yung-Hsiang Lin
-
Patent number: 11040045Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.Type: GrantFiled: April 24, 2020Date of Patent: June 22, 2021Assignee: DSM IP ASSETS B.V.Inventors: Shuen Ei Chen, Thau Kiong Chung, Daniel Raederstorff, Wolfgang Schalch
-
Patent number: 11033553Abstract: An energy-promoting composition includes a stimulant component such as caffeine, a vasodilator component, an energy source including an exogenous ketone body component, and optionally a nootropic component. The separate components beneficially and synergistically interact with one another enhances the overall energy-promoting effect of the composition more rapidly and to a greater degree than if one or more of the components are omitted. The energy-promoting composition is also formulated to minimize the crash effect common to stimulants such as energy drinks.Type: GrantFiled: April 15, 2020Date of Patent: June 15, 2021Assignee: AXCESS GLOBAL SCIENCES, LLCInventor: Gary Millet
-
Patent number: 11020372Abstract: The invention relates to novel methods and compositions for safely reducing negative side effects of cancer treatments. These methods and compositions comprise administering to a patient a composition comprising one or more of the following: curcumin (derived from turmeric), epigallocatechin-3-gallate (EGCG, enriched in green tea), glucosinolates (enriched in cruciferous vegetables) and/or derivatives thereof, such as sulforaphane (SFN), alone or combined with a ketogenic diet or a modified ketogenic diet. Also the current invention relates to a composition comprising medium chain triglycerides (MCT), Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as sulforaphane (SFN).Type: GrantFiled: March 23, 2016Date of Patent: June 1, 2021Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Loic Pierre Deleyrolle, Brent Allan Reynolds
-
Patent number: 11000502Abstract: Copper based antibacterial agents are described based on amphiphilic copper complexes formed between copper and hydroxypyrones, such as maltol. In further aspects, the present invention relates to PEG based-ointments showing that they are particularly effective for topical delivery of amphiphilic complexes of copper. In particular, PEG ointments were shown to limit bacterial growth, even when in the absence of copper agent. However, this bacteriostatic effect is shown herein to become a true biocidal effect when copper hydroxypyrones are added to the PEG.Type: GrantFiled: February 6, 2018Date of Patent: May 11, 2021Assignee: United Kingdom Research and InnovationInventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria, Carlos Andre Passos Bastos
-
Patent number: 10993958Abstract: Compositions comprising aldehyde functional monoterpenoids in combination with 3,3?,4?,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19.Type: GrantFiled: May 22, 2020Date of Patent: May 4, 2021Inventor: William B. Coe